Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is experiencing strong revenue growth, driven by traditional year-end buy-ups and continued conversion to subscription-based arrangements. Their strong gross margins and ability to manage costs have resulted in EBITDA margins of 37%, leading to a significant EPS beat. While 2026 revenue guidance has been lowered due to uncertainty surrounding Most Favored Nation pricing and shorter contract durations, the company has a strong track record of managing costs and a solid customer base of pharmaceutical clients. Their AI capabilities provide potential for further growth and cost savings, and the company has a built-in operating leverage with their current headcount. Overall, the company's strong financial performance and potential for future growth make it a solid investment opportunity with a target price of $17.

Bears say

OptimizeRx is facing challenges with slowing revenue growth and decreased visibility due to uncertainties brought on by "most favored nation" pricing headwinds from the Trump Administration. Furthermore, the company's reliance on a few large pharmaceutical manufacturers for a significant portion of its sales puts it at risk if any of those partnerships were to end. The company has also had a history of needing to raise capital in order to sustain positive cash flow, which could dilute existing shareholders and hinder its ability to aggressively pursue sales and marketing efforts.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.